Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Document series

Draft scope of the analytical and methodological standards series

Consultation on the scope and drafting conventions of the analytical and methodological standards series. The central question put was whether an Institute standard should prescribe a procedure or state the performance a determination must achieve, leaving…

Document identifier
CEI-CP-015
Series
Public comment period
Version
1.0
Published
28 Dec 2023
Last reviewed
28 Dec 2023
Next review
28 Dec 2024
Identifier
10.71829/cei.cp.15
Certainty
Not rated
Cycle
2023 Q4
Window
09 Oct 2023 – 08 Dec 2023
Status
Closed
Submissions
9

§1Consultation and window

§1.1Window

Opened
9 October 2023
Closed
8 December 2023
Duration
60 days
Status
Closed — the disposition is published
Document under consultation
Document series
Submissions received
9

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Should a standard in this series prescribe a procedure or state required performance?
  2. Is the proposed identifier convention, with a version number carried on the face of every determination made under a standard, workable in a laboratory setting?
  3. Should a standard state what a determination made under it does not establish, and if so, where in the document should that statement sit?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The series was scoped to state performance rather than to prescribe procedure, which is the position every subsequent standard has followed. Each standard carries a limitations section, placed before the references rather than in an annex, stating what a determination made under it does not establish.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.